Format

Send to

Choose Destination
Cancer. 2019 Sep 11. doi: 10.1002/cncr.32513. [Epub ahead of print]

Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis.

Author information

1
Department of Medicine, Internal Medicine Residency Training Program, University of Colorado School of Medicine, Aurora, Colorado.
2
Department of Pediatrics, Cancer Center Biostatistics Core, University of Colorado School of Medicine, Aurora, Colorado.
3
Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, Colorado.
4
Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado.
5
Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, Colorado.

Abstract

BACKGROUND:

Previous studies have shown an increased risk of secondary primary malignancies (SPMs) after diffuse large B-cell lymphoma (DLBCL) treatment. Whether stage of DLBCL at diagnosis affects the subtypes of SPMs that occur has not been previously described.

METHODS:

The Surveillance, Epidemiology, and End Results database was queried for patients aged >18 years diagnosed with primary DLBCL from 1973 to 2010 and categorized by early stage (ES) (stage I-II) or advanced stage (AS) (stage III-IV) disease. Differences in overall and location-specific SPM incidence by stage and time since diagnosis were assessed in 5-year intervals using a Fine-Gray hazards model. Overall survival was compared using the log-rank test. A Cox proportional hazards model was used to assess differences in survival.

RESULTS:

In total, 26,038 patients with DLBCL were identified, including 14,724 with ES and 11,314 with AS disease. The median follow-up was 13.3 years. Overall, 13.0% of patients developed SPM, with a higher but nonsignificantly increased risk of SPM development in those who had ES disease compared with those who had AS disease (14% vs 11.6%; P = .14). During the first 5 years after diagnosis, patients who had ES disease had a higher risk of SPM than those who had AS disease, specifically colorectal, pancreas, breast, and prostate SPMs. During the period from 10 to 15 years after diagnosis, patients who had AS disease had a higher risk of SPM than those who had ES disease, specifically hematologic SPMs. Development of SPM was found to significantly increase the risk of death regardless of stage at diagnosis.

CONCLUSIONS:

In this large, population-based study, distinctly different subtypes and temporal patterns of SPM development were identified based on stage of DLBCL at diagnosis. The current study merits consideration of tailored site-specific and time-specific surveillance for patients with DLBCL according to stage and time interval since diagnosis.

KEYWORDS:

diffuse large B-cell lymphoma; non-Hodgkin lymphoma; second primary neoplasms; survivorship

PMID:
31509235
DOI:
10.1002/cncr.32513

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center